Total Payments
$2,762
2023 Payments
$1,064
Companies
44
Transactions
191
Medicare Patients
2,518
Medicare Billing
$231,325
Payment Breakdown by Category
Food & Beverage$2,762 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,762 | 191 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AbbVie Inc. | $518.94 | 38 | $0 (2023) |
| Novo Nordisk Inc | $408.50 | 32 | $0 (2023) |
| PFIZER INC. | $234.41 | 17 | $0 (2022) |
| Lilly USA, LLC | $212.68 | 15 | $0 (2023) |
| Amgen Inc. | $147.28 | 10 | $0 (2023) |
| Astellas Pharma US Inc | $107.77 | 6 | $0 (2023) |
| Merck Sharp & Dohme LLC | $103.45 | 7 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $68.29 | 4 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $68.19 | 5 | $0 (2022) |
| Abbott Laboratories | $62.61 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $1,064 | 73 | Novo Nordisk Inc ($260.21) |
| 2022 | $448.06 | 29 | ABBVIE INC. ($160.37) |
| 2021 | $827.52 | 60 | AbbVie Inc. ($187.71) |
| 2020 | $326.09 | 22 | PFIZER INC. ($81.22) |
| 2019 | $95.99 | 7 | SANOFI-AVENTIS U.S. LLC ($27.89) |
All Payment Transactions
191 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/22/2023 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $13.06 | General |
| Category: Diabetes Care | ||||||
| 12/18/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $20.52 | General |
| Category: NEUROSCIENCE | ||||||
| 12/18/2023 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $16.48 | General |
| Category: Obesity | ||||||
| 12/06/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $17.09 | General |
| Category: Diabetes | ||||||
| 12/05/2023 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $15.07 | General |
| Category: Central Nervous System | ||||||
| 11/08/2023 | AbbVie Inc. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $10.72 | General |
| Category: NEUROSCIENCE | ||||||
| 11/07/2023 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $19.31 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 11/03/2023 | ITI, Inc. | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $15.39 | General |
| Category: PSYCHIATRY | ||||||
| 11/02/2023 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $11.39 | General |
| Category: Obesity | ||||||
| 10/30/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $14.52 | General |
| Category: Diabetes | ||||||
| 10/27/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $13.71 | General |
| Category: Diabetes | ||||||
| 10/26/2023 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: Biological | ||||||
| 10/24/2023 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $16.66 | General |
| Category: Neuropsychiatry | ||||||
| 10/19/2023 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $18.96 | General |
| Category: UROLOGY | ||||||
| 10/16/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.91 | General |
| Category: NEUROSCIENCE | ||||||
| 10/13/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $12.80 | General |
| Category: Diabetes | ||||||
| 10/11/2023 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $20.00 | General |
| Category: PSYCHIATRY | ||||||
| 10/10/2023 | AbbVie Inc. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $17.56 | General |
| Category: NEUROSCIENCE | ||||||
| 10/03/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $15.67 | General |
| Category: Diabetes | ||||||
| 09/26/2023 | IMPEL PHARMACEUTICALS INC. | Trudhesa (Drug) | Food and Beverage | Cash or cash equivalent | $13.52 | General |
| Category: Neurology | ||||||
| 09/13/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.14 | General |
| Category: DIABETES | ||||||
| 09/11/2023 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $13.62 | General |
| Category: UROLOGY | ||||||
| 09/07/2023 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $16.61 | General |
| Category: Inflammation | ||||||
| 09/05/2023 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $14.85 | General |
| Category: PSYCHIATRY | ||||||
| 08/28/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $13.20 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 785 | 1,656 | $157,942 | $68,198 |
| 2022 | 13 | 779 | 1,566 | $160,178 | $74,457 |
| 2021 | 12 | 506 | 1,169 | $112,677 | $52,970 |
| 2020 | 6 | 448 | 668 | $76,696 | $35,700 |
Total Patients
2,518
Total Services
5,059
Medicare Billing
$231,325
Procedure Codes
47
All Medicare Procedures & Services
47 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 239 | 671 | $121,764 | $52,408 | 43.0% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 45 | 47 | $9,088 | $3,476 | 38.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 203 | 316 | $2,528 | $2,477 | 98.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 30 | 31 | $3,783 | $1,786 | 47.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 13 | 13 | $2,534 | $1,540 | 60.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 50 | 52 | $2,284 | $1,521 | 66.6% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2023 | 25 | 27 | $2,091 | $1,358 | 64.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 12 | 12 | $3,364 | $1,016 | 30.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 38 | 103 | $4,723 | $990.18 | 21.0% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 46 | 71 | $1,917 | $675.92 | 35.3% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2023 | 17 | 36 | $1,188 | $583.92 | 49.2% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 24 | 27 | $1,350 | $217.04 | 16.1% |
| 81002 | Urinalysis, manual test | Office | 2023 | 23 | 38 | $228.00 | $129.58 | 56.8% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 20 | 212 | $1,100 | $19.75 | 1.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 249 | 696 | $124,861 | $59,132 | 47.4% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 54 | 55 | $7,251 | $3,860 | 53.2% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2022 | 47 | 55 | $4,235 | $2,737 | 64.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 24 | 24 | $6,624 | $2,293 | 34.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 24 | 34 | $4,089 | $1,846 | 45.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 58 | 59 | $2,478 | $1,705 | 68.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 38 | 90 | $4,104 | $914.35 | 22.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 179 | 284 | $2,640 | $837.94 | 31.7% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2022 | 12 | 26 | $874.00 | $423.04 | 48.4% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 39 | 40 | $1,086 | $373.40 | 34.4% |
| 81002 | Urinalysis, manual test | Office | 2022 | 27 | 44 | $314.00 | $150.97 | 48.1% |
About Dr. Michael Sands, DO
Dr. Michael Sands, DO is a Family Medicine healthcare provider based in Jefferson City, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/27/2007. The National Provider Identifier (NPI) number assigned to this provider is 1558551358.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Sands, DO has received a total of $2,762 in payments from pharmaceutical and medical device companies, with $1,064 received in 2023. These payments were reported across 191 transactions from 44 companies. The most common payment nature is "Food and Beverage" ($2,762).
As a Medicare-enrolled provider, Sands has provided services to 2,518 Medicare beneficiaries, totaling 5,059 services with total Medicare billing of $231,325. Data is available for 4 years (2020–2023), covering 47 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Jefferson City, MO
- Active Since 07/27/2007
- Last Updated 03/05/2020
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1558551358
Products in Payments
- VRAYLAR (Drug) $291.31
- Ozempic (Drug) $212.20
- Wegovy (Drug) $100.79
- COLOGUARD DNA CAPTURE REAGENTS (Device) $100.61
- UBRELVY (Drug) $99.95
- MOUNJARO (Drug) $96.37
- JARDIANCE (Drug) $91.41
- Rybelsus (Drug) $81.90
- QULIPTA (Drug) $67.60
- NURTEC ODT (Drug) $66.32
- REXULTI (Drug) $64.71
- Otezla (Drug) $64.14
- BELSOMRA (Drug) $56.79
- INGREZZA (Drug) $56.52
- Aimovig (Biological) $52.58
- SPIRIVA RESPIMAT (Drug) $48.15
- LINZESS (Drug) $47.08
- Veozah (Drug) $45.74
- TRULICITY (Drug) $45.04
- CAPLYTA (Drug) $43.38
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Jefferson City
Dr. George Carr, Md, MD
Family Medicine — Payments: $45,033
Family Medicine $45,033
Dr. Eric Caywood, D.o, D.O
Family Medicine — Payments: $17,382
Family Medicine $17,382
Dustin Warbritton, D.o, D.O
Family Medicine — Payments: $13,272
Family Medicine $13,272
Benjamin Cook, Do, DO
Family Medicine — Payments: $9,154
Family Medicine $9,154
Dr. Michael Steenbergen, M.d, M.D
Family Medicine — Payments: $9,039
Family Medicine $9,039
Dr. Saira Babar, M.d, M.D
Family Medicine — Payments: $7,055
Family Medicine $7,055